he's on to the next multibagger.
Big Pharmas Eyeing ESPR, Founder Recreated Lipitor & Made Them Billions.
Adam Feuerstein @adamfeuerstein 23m23 minutes ago
$PBYI up to 17% of women taking neratinib still have grade 3 diarrhea despite huge doses of Imodium. Bet they feel great! #ASCO15
6 Key Cancer Winners From ASCO Presentations
By Chris Lange June 1, 2015 9:40 am EDT
Vascular Biogenics Ltd. (NASDAQ: VBLT) announced interim results for its ongoing Phase 2 study of VB-111 in patients with recurring glioblastoma. Overall, the data presented showed a statistically significant overall survival benefit. Shares of Vascular Biogenics closed Friday up 9.1% at $8.05 to close outfor a strong week. In early trading, shares rose 5% to $8.45. The stock has a consensus analyst price target of $13.00.
ASCO 2015: ( DCTH ) Delcath Systems Shows Life-Extending Results Treating Liver Cancer Patients
By The ASCO Post
Posted: 5/31/2015 7:50:52 PM
Clinicians continue to produce positive, life-extending results treating liver cancer patients with CHEMOSAT in multiple tumor types
CHEMOSAT is well tolerated and is an easy-to-learn procedure for an experienced treatment team
Multiple treatment courses of at least four procedures have been shown to be safe and well tolerated while continuing to provide clinical benefit and good quality of life